MedTrace Logo

Uric Acid and the Endothelium in CKD

NCT01228903 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2017-06-28

Study results available
· View outcomes & findings →

Summary

This study will test the hypothesis that uric acid impairs the function of vessels in patients with kidney disease

Conditions

Interventions

DRUG

Allopurinol

Xanthine oxidase inhibitor- effective at lowering uric acid levels.

OTHER

Placebo

Placebo tablets with no active ingredient

Sponsors & Collaborators

  • National Institutes of Health (NIH)

    collaborator NIH

  • National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

    collaborator NIH

  • University of Colorado, Denver

    lead OTHER

Principal Investigators

  • Diana Jalal, MD · University of Colorado, Denver

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-10-31
Primary Completion
2016-09-30
Completion
2016-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01228903 on ClinicalTrials.gov